Navidea Biopharmaceuticals Brief Analyst Report by Small Cap Street and BrokerBank Securities, Inc.

NEW YORK, Sept. 29, 2014 /PRNewswire/ -- Navidea Biopharmaceuticals, Inc. (NYSEMKT: NAVB) – The usage of medical imaging, which creates visual representations of the interior of a patient's body for clinical analysis and medical intervention, has increased significantly. According to Nature magazine use of computed tomography exams in the United States, including X-rays and CAT scans, has increased from approximately 120 scans per 1,000 people in 2000, to 270 scans per 1000 people in 2011. In 2007 alone, an estimated 72 million scans were performed. While beneficial in the detection and prevention of diseases, these scans are expensive and expose the patient to a significant level of radiation.  In 2006, exposure to radiation from medical imaging was approximately 50% of total ionizing radiation exposure in the United States. Ionizing radiation can create a health hazard and demand for precision imaging to reduce exposure to potentially dangerous levels radiation is increasing.

Navidea Biopharmaceuticals, Inc. (AMEX: NAVB), is a biopharmaceutical company focused on improving diagnostic accuracy in the detection of various diseases including Alzheimer's disease, cancer, and Parkinson's disease through the development and commercialization of precision diagnostic and radiopharmaceutical imaging agents. These precision diagnostics are used to pinpoint molecular sites and pathways to identify the presence and status of diseases. The company's Lymphoseek® injection has been approved by the FDA for patients with several different types of solid tumor cancers and two other imaging agents are in Phase 3 development.

A brief analyst report on NAVB that includes recent events and the stock's technical outlook can be viewed by using the following link at no cost:

http://bit.ly/-NAVB-AnalystBrief

Copy and paste to browser may be required.

About Small Cap Street

Once you read our reports written by our team of financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties at no cost.

Our Financial Analysts spend countless hours researching stocks. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges. These reports include a straightforward assessment of the company by a financial analyst who has pledged to remain free of influence when writing research reports.

Forward-Looking Disclaimer   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

Compliance Procedure   

Content is researched, written and reviewed on a best-effort basis. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the full analyst report.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries please contact us at [email protected].  

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

SOURCE Small Cap Street